LACTOLOGY FOUNDATION

Antacids with antiflatulents (ATC class A02AF) are combination products used to relieve upper dyspepsia symptoms where gastric hyperacidity and gas-related discomfort (bloating, flatulence) coexist. From a toxico‑lactological standpoint, they are generally considered low‑risk in breastfeeding because both the antacid components and simethicone/other antiflatulents have minimal systemic absorption in the mother and negligible transfer into breast milk.

Drug class overview (ATC A02AF)

• ATC A02AF comprises antacids combined with antiflatulents, classified under A02A “Antacids” within the ATC system.
• Subcodes include A02AF01 (magaldrate and antiflatulents) and A02AF02 (ordinary salt combinations and antiflatulents).
• These preparations are primarily indicated for symptom relief in gastro‑oesophageal reflux, dyspepsia and heartburn associated with gas accumulation and bloating.

Typical active ingredients

• Antacid components: aluminum hydroxide, magnesium hydroxide, magnesium carbonate, magaldrate and related salts, often used in fixed combinations to balance constipating and laxative effects.
• Antiflatulents: mainly simethicone (dimethicone), which reduces surface tension of gas bubbles in the gut, thus facilitating coalescence and elimination of gas without systemic pharmacological action.

Mechanism of action and clinical use

• The antacid fraction neutralizes gastric hydrochloric acid, increasing intragastric pH and thus reducing peptic activity and acid‑mediated mucosal irritation.
• The antiflatulent fraction (classically simethicone) acts locally in the gastrointestinal lumen to disperse and break up gas bubbles, relieving pressure, abdominal distension and pain; it is not absorbed into the bloodstream.
• Clinically, A02AF products are used intermittently, on demand, often after meals and at bedtime, to manage episodic heartburn, dyspepsia and post‑prandial bloating; they are not intended for long‑term monotherapy of ulcer disease.

Safety profile in the general population

• Antacids are generally well tolerated; common adverse effects are gastrointestinal, such as constipation (aluminum‑rich products) and diarrhea (magnesium‑rich products).
• Prolonged high‑dose use can theoretically disturb electrolyte balance (e.g. hypermagnesemia, aluminum accumulation in renal impairment) and interfere with absorption of concomitant oral drugs (tetracyclines, quinolones, certain azoles, iron, digoxin, isoniazid and others) via chelation or pH change.
• Simethicone has an excellent safety profile because of its lack of systemic absorption and is also used directly in infants to treat gas‑related discomfort.

Toxico‑lactological assessment

Pharmacokinetic considerations during lactation

• Classical antacid ingredients (aluminum hydroxide, magnesium hydroxide, magnesium carbonate, magaldrate) act locally in the gastric lumen and exhibit very limited gastrointestinal absorption in healthy adults.
• Systemic bioavailability is low; any absorbed fraction is small and subject to renal elimination, which markedly limits the potential amount that could appear in breast milk.
• Simethicone acts exclusively within the gastrointestinal tract, is not measurably absorbed, and therefore does not reach maternal plasma or breast milk.

Evidence for breastfeeding safety

• Guidance on treating heartburn and dyspepsia during breastfeeding from UK NHS specialist pharmacy services states that antacids, alginates and simethicone have poor oral bioavailability and that exposure of the breastfed infant via milk will be minimal, making them suitable first‑line options when lifestyle measures are insufficient.
• NHS patient information explicitly notes that simethicone is safe in breastfeeding and does not get into breast milk; similar advice is given for pregnancy.
• Medicine‑specific data (e.g. for aluminum hydroxide/magnesium hydroxide/simethicone combinations) indicate that simethicone is considered safe during lactation and is itself used therapeutically in infants.

Expected lactation risk category (conceptual)

If we map the available data to your own four‑tier toxico‑lactological categorization scheme (I–IV, as outlined on the Bulgarian page you provided):

• Antacid component: With minimal systemic absorption and long history of safe use, standard‑dose aluminum/magnesium antacids would usually fall in a low‑risk group, conceptually close to your lactation category II (measurable, but clinically irrelevant exposure).
• Simethicone/antiflatulent component: Because it is not absorbed and does not enter breast milk, simethicone corresponds closely to your lactation category I (no transfer into milk and no toxicity for the infant).
• Combination product (class A02AF): The overall risk assessment is driven by the more toxicologically relevant antacid fraction, but in usual doses and in healthy, term breastfed infants, the combination would typically be classified as low‑risk, operationally between your lactation categories I and II.

In clinical practice, this supports continued breastfeeding without interruption when A02AF medicines are indicated, especially with short‑term, on‑demand use, provided maternal renal function is normal and dosing remains within recommended ranges.

Special populations, precautions and interactions

• Premature infants, neonates with renal impairment and those with significant comorbidities are theoretically more vulnerable to electrolyte disturbances if maternal antacid exposure were extreme, although typical maternal dosing is unlikely to generate clinically significant milk levels.
• In mothers with severe renal impairment, chronic high‑dose antacid use can lead to elevated serum magnesium or aluminum, so a more cautious approach (short courses, preference for non‑aluminum formulations, or alternative therapy) is reasonable, with individual toxico‑lactological assessment.
• Clinicians should consider interactions with other maternal medications: antacids can reduce gastrointestinal absorption of certain antibiotics, bisphosphonates, levothyroxine, iron and other oral drugs; this affects maternal treatment efficacy rather than infant safety but is relevant for overall therapeutic planning in breastfeeding women.

Practical toxico‑lactological guidance for A02AF

• For short‑term, on‑demand use in otherwise healthy breastfeeding women, A02AF combinations are compatible with continued breastfeeding and do not require routine interruption or milk discarding.
• When prolonged daily use is anticipated, clinicians should review renal function, total antacid load and concomitant medications and consider stepping up to H2‑receptor antagonists or PPIs with well‑characterised breastfeeding safety profiles if symptom control requires long‑term acid suppression.
• Individual risk–benefit assessment should always prioritize maternal symptom control and quality of life, while recognizing that the infant exposure from these preparations is extremely low and that uncontrolled maternal disease may itself impair breastfeeding or overall health.